Allred Capital Management LLC Has $4.81 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Allred Capital Management LLC reduced its holdings in Johnson & Johnson (NYSE:JNJFree Report) by 0.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 30,656 shares of the company’s stock after selling 261 shares during the quarter. Johnson & Johnson comprises 2.1% of Allred Capital Management LLC’s holdings, making the stock its 8th largest holding. Allred Capital Management LLC’s holdings in Johnson & Johnson were worth $4,805,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the business. DORCHESTER WEALTH MANAGEMENT Co increased its holdings in shares of Johnson & Johnson by 0.6% during the third quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 75,495 shares of the company’s stock valued at $11,758,000 after acquiring an additional 414 shares in the last quarter. OneAscent Financial Services LLC increased its holdings in shares of Johnson & Johnson by 82.8% during the fourth quarter. OneAscent Financial Services LLC now owns 9,838 shares of the company’s stock valued at $1,542,000 after acquiring an additional 4,457 shares in the last quarter. TrueMark Investments LLC bought a new stake in shares of Johnson & Johnson during the fourth quarter valued at approximately $1,458,000. Cibc World Market Inc. increased its holdings in shares of Johnson & Johnson by 4.4% during the second quarter. Cibc World Market Inc. now owns 702,435 shares of the company’s stock valued at $116,267,000 after acquiring an additional 29,891 shares in the last quarter. Finally, RAM Investment Partners LLC grew its holdings in Johnson & Johnson by 4.5% during the fourth quarter. RAM Investment Partners LLC now owns 1,688 shares of the company’s stock worth $265,000 after buying an additional 73 shares in the last quarter. 68.40% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages recently issued reports on JNJ. UBS Group upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and upped their price target for the stock from $167.00 to $180.00 in a report on Friday, December 1st. Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 price target on shares of Johnson & Johnson in a report on Wednesday, February 28th. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Wednesday, March 13th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Finally, Wells Fargo & Company downgraded shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and cut their price target for the stock from $170.00 to $163.00 in a report on Wednesday, December 13th. Seven equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average price target of $177.31.

View Our Latest Report on JNJ

Insider Buying and Selling

In related news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the transaction, the insider now directly owns 4,099,575 shares in the company, valued at $105,810,030.75. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of the stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the transaction, the insider now directly owns 4,099,575 shares in the company, valued at $105,810,030.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Jennifer L. Taubert sold 59,397 shares of the stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the transaction, the executive vice president now owns 141,416 shares in the company, valued at $22,099,078.32. The disclosure for this sale can be found here. 0.20% of the stock is owned by company insiders.

Johnson & Johnson Trading Down 0.3 %

Shares of Johnson & Johnson stock opened at $155.23 on Monday. Johnson & Johnson has a 12-month low of $144.95 and a 12-month high of $175.97. The company has a market cap of $374.07 billion, a price-to-earnings ratio of 11.24, a PEG ratio of 2.61 and a beta of 0.53. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.38. The company’s 50-day moving average price is $159.00 and its 200-day moving average price is $156.75.

Johnson & Johnson (NYSE:JNJGet Free Report) last announced its quarterly earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.28 by $0.01. The firm had revenue of $21.40 billion for the quarter, compared to the consensus estimate of $21.02 billion. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. The company’s revenue for the quarter was down 9.7% on a year-over-year basis. During the same period in the prior year, the firm posted $2.35 earnings per share. On average, equities analysts expect that Johnson & Johnson will post 10.65 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 5th. Investors of record on Tuesday, February 20th were given a $1.19 dividend. This represents a $4.76 annualized dividend and a dividend yield of 3.07%. The ex-dividend date was Friday, February 16th. Johnson & Johnson’s dividend payout ratio (DPR) is 34.47%.

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.